Mitochondrial Targeting and pH-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance

Multidrug resistance (MDR) is one of the leading causes of the failure of cancer chemotherapy and mainly attributed to the overexpression of drug efflux transporters in cancer cells, which is dependent on adenosine triphosphate (ATP). To overcome this phenomenon, herein, a mitochondrial-directed pH-sensitive polyvinyl alcohol (PVA) nanogel incorporating the hexokinase inhibitor lonidamine (LND) and the chemotherapeutic drug paclitaxel (PTX) was developed to restore the activity of PTX and synergistically treat drug-resistant tumors. The introduction of 2-dimethylaminoethanethiol (DMA) moiety into the nanogels not only promoted the drug loading capacity but also enabled the lysosomal escape of the nanogels. The subsequent mitochondrial targeting facilitated the accumulation and acid-triggered payload release in the mitochondria. The released LND can destroy the mitochondria by exhausting the mitochondrial membrane potential (MMP), generating reactive oxygen species (ROS) and restraining the energy supply, resulting in apoptosis and susceptibility of the MCF-7/MDR cells to PTX. Hence, the nanogel-enabled combination regimen of LND and PTX showed a boosted anti-tumor efficacy in MCF-7/MDR cells. These mitochondrial-directed pH-sensitive PVA nanogels incorporating both PTX and LND represent a new nanoplatform for MDR reversal and enhanced therapeutic efficacy.

[1]  S. Yao,et al.  Mito‐Bomb: Targeting Mitochondria for Cancer Therapy , 2021, Advanced materials.

[2]  Haishi Qiao,et al.  Inherently nitric oxide containing polymersomes remotely regulated by NIR for improving multi-modal therapy on drug resistant cancer. , 2021, Biomaterials.

[3]  Kui Luo,et al.  Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition. , 2021, ACS applied materials & interfaces.

[4]  Li Hai,et al.  Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine. , 2021, ACS applied materials & interfaces.

[5]  Lanlan Zong,et al.  A novel GSH-triggered polymeric nanomicelles for reversing MDR and enhancing antitumor efficiency of Hydroxycamptothecin. , 2021, International journal of pharmaceutics.

[6]  Tingting Qin,et al.  Combined nanosuspensions from two natural active ingredients for cancer therapy with reduced side effects , 2021 .

[7]  N. Peppas,et al.  A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting , 2021, Science Advances.

[8]  Yongzhen Peng,et al.  The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment , 2020, Cancers.

[9]  R. Haag,et al.  Tumor Microenvironment‐Activatable Nanoenzymes for Mechanical Remodeling of Extracellular Matrix and Enhanced Tumor Chemotherapy , 2020, Advanced Functional Materials.

[10]  N. Peppas,et al.  Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites. , 2020, Advanced drug delivery reviews.

[11]  Lanlan Zong,et al.  Reduction-sensitive poly(ethylene glycol)–polypeptide conjugate micelles for highly efficient intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin , 2020, Nanotechnology.

[12]  Haishi Qiao,et al.  Functional Biodegradable Nitric Oxide Donor-Containing Polycarbonate-Based Micelles for Reduction-Triggered Drug Release and Overcoming Multidrug Resistance. , 2019, ACS macro letters.

[13]  Y. Assaraf,et al.  The multi-factorial nature of clinical multidrug resistance in cancer. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  Mohammad Ramezani,et al.  Enzyme responsive drug delivery systems in cancer treatment. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[15]  J. Feijen,et al.  Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy. , 2019, Biomaterials science.

[16]  L. Ouyang,et al.  Tumor Microenvironment‐Responsive Dual Drug Dimer‐Loaded PEGylated Bilirubin Nanoparticles for Improved Drug Delivery and Enhanced Immune‐Chemotherapy of Breast Cancer , 2019, Advanced Functional Materials.

[17]  T. Minko,et al.  Nanocarrier-based systems for targeted and site specific therapeutic delivery. , 2019, Advanced drug delivery reviews.

[18]  Lanlan Zong,et al.  A polymeric micelle with an endosomal pH-sensitivity for intracellular delivery and enhanced antitumor efficacy of hydroxycamptothecin. , 2019, Acta biomaterialia.

[19]  R. Haag,et al.  Directed Graphene-Based Nanoplatforms for Hyperthermia: Overcoming Multiple Drug Resistance. , 2018, Angewandte Chemie.

[20]  Fabian Kiessling,et al.  Tumor targeting via EPR: Strategies to enhance patient responses. , 2018, Advanced drug delivery reviews.

[21]  Mengjiao Zhou,et al.  Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance. , 2017, ACS applied materials & interfaces.

[22]  R. Haag,et al.  pH‐degradable PVA‐based nanogels via photo‐crosslinking of thermo‐preinduced nanoaggregates for controlled drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[23]  R. Zhou,et al.  Mechanism of antineoplastic activity of lonidamine. , 2016, Biochimica et biophysica acta.

[24]  Y. Baran,et al.  Molecular mechanisms of drug resistance and its reversal in cancer , 2016, Critical reviews in biotechnology.

[25]  Y. Assaraf,et al.  Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  Can Zhang,et al.  Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. , 2015, Biomaterials.

[27]  Lei Xing,et al.  Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine. , 2015, Biomaterials.

[28]  D. Heitjan,et al.  Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin , 2015, NMR in Biomedicine.

[29]  A. M. Al-Abd,et al.  P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review , 2014, Journal of advanced research.

[30]  S. Cole.  Multidrug Resistance Protein 1 (MRP1, ABCC1), a “Multitasking” ATP-binding Cassette (ABC) Transporter* , 2014, The Journal of Biological Chemistry.

[31]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[32]  M. Rebucci,et al.  Molecular aspects of cancer cell resistance to chemotherapy. , 2013, Biochemical pharmacology.

[33]  Jia Zhou,et al.  Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. , 2013, Biomaterials.

[34]  D. Heitjan,et al.  31P and 1H MRS of DB‐1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan , 2013, NMR in biomedicine.

[35]  H. Lage.  An overview of cancer multidrug resistance: a still unsolved problem , 2008, Cellular and Molecular Life Sciences.

[36]  K P Fung,et al.  Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. , 2002, Life sciences.

[37]  D. Thrall,et al.  Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs , 1996, Cancer Chemotherapy and Pharmacology.

[38]  B. Silvestrini,et al.  Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.